Table 2 Univariate survival analyses.
From: Anti-IL-20 monoclonal antibody inhibited tumor growth in hepatocellular carcinoma
Parameter | No. of Case | OS | LRFS | ||
---|---|---|---|---|---|
No. Event | P-value | No. Event | P-value | ||
Sex | 0.8128 | ||||
Male | 84 | 27 | 47 | 0.3931 | |
Female | 20 | 8 | 10 | ||
Age (years) | 0.6115 | 0.1427 | |||
<60 | 48 | 15 | 22 | ||
≧60 | 56 | 20 | 35 | ||
Pugh-Child’s Classification | |||||
A | 85 | 23 | <0.0001* | 43 | <0.0001* |
B | 6 | 6 | 6 | ||
C | 3 | 3 | 3 | ||
AFP | 0.0556 | 0.1840 | |||
<400 | 75 | 19 | 37 | ||
≧400 | 23 | 10 | 14 | ||
Tumor Multiplicity | <0.0001* | <0.0001* | |||
Solitary | 61 | 8 | 22 | ||
Multiple | 43 | 27 | 35 | ||
Differentiation | |||||
Well/Moderately differentiated | 79 | 21 | 0.0010* | 39 | 0.0015* |
Poorly differentiated | 25 | 14 | 18 | ||
Primary Tumor (pT) | 0.0003* | 0.0017* | |||
pT1 | 42 | 6 | 16 | ||
pT2 | 32 | 13 | 20 | ||
pT3–4 | 30 | 16 | 21 | ||
AJCC Stage | <0.0001* | 0.0003* | |||
Stage I | 40 | 4 | 14 | ||
Stage II | 32 | 13 | 20 | ||
Stage III-V | 32 | 18 | 23 | ||
CLIP score | 0.0008* | 0.0001* | |||
0–1 | 63 | 15 | 29 | ||
2–3 | 30 | 16 | 22 | ||
Okuda stage | 0.0005* | 0.0748 | |||
I | 62 | 14 | 31 | ||
II-III | 31 | 17 | 20 | ||
IL-20 | <0.0001* | <0.0001* | |||
Low expression (<5%) | 52 | 8 | 19 | ||
High expression (≧5%) | 52 | 27 | 38 |